Business Context and Reporting Period
Company: Aspire Biopharma Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 15, 2025
Reporting Period: Event-based report regarding Nasdaq listing compliance status.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, or debt levels. The only financial figure disclosed is the $20,000 fee paid to the Nasdaq Hearings Panel to stay the suspension of trading.
Material Changes and Listing Status
- Delisting Notice: On October 15, 2025, Nasdaq notified the Company that its securities are subject to delisting due to failure to regain compliance with two listing rules within the 180-day compliance period.
- Market Value of Listed Securities (MVLS): The Company failed to maintain the required minimum MVLS of $50,000,000 for 10 consecutive trading days.
- Bid Price: The Company failed to maintain the required minimum bid price of $1.00 per share.
- Current Status: Trading of Common Stock (ASBP) and Warrants (ASBPW) has been stayed pending the decision of the Nasdaq Hearings Panel.
Outlook, Management Commentary, and Risks
- Appeal Process: The Company has requested a hearing before the Nasdaq Hearings Panel and paid the requisite fee.
- Management Plan: At the hearing, management will present a plan to regain compliance and request an extension of time (up to 180 days).
- Risks and Uncertainty: There is no assurance that the Panel will grant the request for continued listing or that the Company will be able to regain compliance within any granted timeframe. Both non-compliance items serve as independent bases for delisting.
Investor Verification Checklist
- Verify the current trading status of ASBP and ASBPW on Nasdaq following the stay of suspension.
- Monitor the date and outcome of the hearing before the Nasdaq Hearings Panel.
- Review the Company's specific plan to increase Market Value of Listed Securities and Bid Price.
- Check for subsequent filings regarding the Panel's decision on the extension request.